<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620515</url>
  </required_header>
  <id_info>
    <org_study_id>NX03-0040</org_study_id>
    <nct_id>NCT01620515</nct_id>
  </id_info>
  <brief_title>Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer</brief_title>
  <official_title>Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nymox Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nymox Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of a single injection of NX-1207
      for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients
      currently undergoing active surveillance. Study participants currently on active surveillance
      will be randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5
      mg or 15 mg) followed by active surveillance or to no treatment (continued active
      surveillance). Blinded efficacy evaluation will be by a second post-treatment prostate
      biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2012</start_date>
  <completion_date type="Actual">October 21, 2015</completion_date>
  <primary_completion_date type="Actual">October 21, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable cancer post-treatment in the region of the prostate where the baseline cancer was detected.</measure>
    <time_frame>Baseline to 45 days post-treatment</time_frame>
    <description>The primary efficacy endpoint is the percentage of subjects with undetectable prostate cancer (negative biopsy) in the region of the prostate where the baseline cancer was detected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of a single treatment of NX-1207 2.5 mg or NX-1207 15 mg in subjects with biopsy-confirmed low grade low risk localized (T1c) prostate cancer.</measure>
    <time_frame>Baseline to 60 days post-treatment</time_frame>
    <description>Safety will be assessed by physical exam, prostate biopsy, monitoring of adverse events, changes in ECG, and changes in PSA and other clinical laboratory values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor grade in the region of the baseline prostate cancer</measure>
    <time_frame>Baseline to 45 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume in the region of the baseline prostate cancer</measure>
    <time_frame>Baseline to 45 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor grade for the whole prostate</measure>
    <time_frame>Baseline to 45 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume in the whole prostate</measure>
    <time_frame>Baseline to 45 days post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Active Surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NX-1207 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NX-1207 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-1207 2.5 mg</intervention_name>
    <description>A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.</description>
    <arm_group_label>NX-1207 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-1207 15 mg</intervention_name>
    <description>A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.</description>
    <arm_group_label>NX-1207 15 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T1c prostate cancer

          -  Gleason score ≤ 6 with no Gleason pattern of 4 or 5.

          -  Life expectancy ≥ 5 years.

          -  Single positive prostate biopsy core with ≤ 50% cancer

          -  PSA ≤ 10 ng/mL

        Exclusion Criteria:

          -  Previous active treatment (such as surgery, brachytherapy, radiotherapy) for prostate
             cancer.

          -  Evidence of metastatic disease or previous positive bone scan.

          -  Previous hormonal therapy for prostate cancer.

          -  Use of certain concomitant medications, including 5 alpha reductase inhibitors (e.g.
             finasteride, dutasteride), androgen receptor blockers (e.g. flutamide, bicalutamide),
             immunosuppressants(such as Imuran™, Enbrel™, Remicade™, Humira™, etc.),
             anticoagulants(such as Coumadin™ or heparin), or chemotherapeutics.

          -  Previous surgical or invasive prostate treatments such as TURP, TUMT, TUNA, laser or
             any other minimally invasive treatment within the past 12 months.

          -  Pelvic irradiation.

          -  Urinary tract infection more than once in the past 12 months.

          -  Acute or chronic prostatitis in the past 12 months.

          -  Clinically significant renal or hepatic impairment.

          -  Bleeding disorder.

          -  Poorly controlled diabetes type 1 or type 2.

          -  Urinary retention in the previous 12 months.

          -  Self-catheterization for urinary retention.

          -  Post-void residual urine volume &gt; 200 mL.

          -  Prior significant rectal surgery or any rectal condition with rectal stenosis or
             fistula.

          -  History of alcohol or substance abuse or dependence within the past 2 years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Atherton</city>
        <state>California</state>
        <zip>94027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <disposition_first_submitted>March 9, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 10, 2017</disposition_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Localized Prostate Cancer</keyword>
  <keyword>T1c Prostate Cancer</keyword>
  <keyword>Focal Therapy</keyword>
  <keyword>NX-1207</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

